New RA drug LFD-200 enters early human testing
Symptom relief
Recruiting now
This early-stage study tests a new drug called LFD-200 in healthy volunteers and people with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body processes the drug. Researchers will give single or multiple doses and watch for side effec…
Phase: PHASE1 • Sponsor: Lifordi Immunotherapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC